295 related articles for article (PubMed ID: 22245694)
1. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B
Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
[TBL] [Abstract][Full Text] [Related]
2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
Davies MJ; Kela R; Khunti K
Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
[TBL] [Abstract][Full Text] [Related]
4. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
5. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide in oral antidiabetic drug combination therapy.
Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
[TBL] [Abstract][Full Text] [Related]
9. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
Vilsbøll T; Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide: a new treatment for type 2 diabetes.
Vilsboll T
Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
[TBL] [Abstract][Full Text] [Related]
11. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Bode B
Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
[TBL] [Abstract][Full Text] [Related]
13. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
14. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide: effects beyond glycaemic control in diabetes treatment.
McGill JB
Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR
Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
[TBL] [Abstract][Full Text] [Related]
17. [GLP-1 mimetics in clinical studies. Treatment by activation of the GLP-1 receptor].
Ritzel RA
Pharm Unserer Zeit; 2010 Mar; 39(2):120-5. PubMed ID: 20196040
[No Abstract] [Full Text] [Related]
18. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
19. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
20. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi G
G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
